share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股SEC公告 ·  2024/11/05 06:24

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals has announced a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of common stock with an aggregate offering price of up to $3,556,586. The sales may occur from time to time through A.G.P., acting as the sales agent or principal. Conduit Pharmaceuticals, an emerging growth company listed under the symbol 'CDT' on the Nasdaq Global Market, plans to use the initial proceeds to repay approximately $600,000 in principal from a Bridge Loan Agreement with A.G.P. The company's common stock last traded at $0.091 per share as of October 31, 2024. This move is part of Conduit Pharmaceuticals' efforts to raise capital for working capital and general corporate purposes, including the development of their clinical assets targeting a range of autoimmune disorders.
Conduit Pharmaceuticals has announced a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of common stock with an aggregate offering price of up to $3,556,586. The sales may occur from time to time through A.G.P., acting as the sales agent or principal. Conduit Pharmaceuticals, an emerging growth company listed under the symbol 'CDT' on the Nasdaq Global Market, plans to use the initial proceeds to repay approximately $600,000 in principal from a Bridge Loan Agreement with A.G.P. The company's common stock last traded at $0.091 per share as of October 31, 2024. This move is part of Conduit Pharmaceuticals' efforts to raise capital for working capital and general corporate purposes, including the development of their clinical assets targeting a range of autoimmune disorders.
Conduit製藥公司宣佈與A.G.P./全球合作伙伴簽訂了銷售協議，以最高爲3,556,586美元的總價提供和出售普通股份。銷售可能隨時通過A.G.P.作爲銷售代理人或委託人進行。作爲一家新興增長型公司，Conduit製藥公司的普通股在納斯達克全球市場上以'CDT'標的上市，計劃使用首次收益償還與A.G.P.的一份橋樑貸款協議約60萬美元的本金。截至2024年10月31日，該公司的普通股最近以每股0.091美元交易。此舉是Conduit製藥公司爲籌集工作資本和一般企業用途資金，包括開發針對一系列自身免疫疾病的臨床資產而採取的措施。
Conduit製藥公司宣佈與A.G.P./全球合作伙伴簽訂了銷售協議，以最高爲3,556,586美元的總價提供和出售普通股份。銷售可能隨時通過A.G.P.作爲銷售代理人或委託人進行。作爲一家新興增長型公司，Conduit製藥公司的普通股在納斯達克全球市場上以'CDT'標的上市，計劃使用首次收益償還與A.G.P.的一份橋樑貸款協議約60萬美元的本金。截至2024年10月31日，該公司的普通股最近以每股0.091美元交易。此舉是Conduit製藥公司爲籌集工作資本和一般企業用途資金，包括開發針對一系列自身免疫疾病的臨床資產而採取的措施。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間